Eikon reports Q3 2026 results, ESMO oncology data and new prostate cancer INDNov 12Quarterly updateAkari Therapeutics PlcAtrium Therapeutics
FDA accelerated approval covers Padcev plus Keytruda in urothelial carcinomaNov 9Regulatory decisionenfortumab vedotinMerck & Co., Inc.
Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics
FDA approves Janssen's gemcitabine system for bladder cancerNov 6Regulatory decisiongemcitabineJohnson & Johnson
Merck collaborator posts pancreatic cancer results; new MK-1045, COPD trial records surfaceNov 6Weekly roundup, 14 itemsDaiichi SankyoensifentrineUpdated
Regeneron-linked TOP2201 posts results; NeoSTOP-IT terminated, DEUTERON completedNov 5Weekly roundup, 7 itemsafliberceptALN-CIDEBUpdated
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
Zentalis-supplied Phase 2 pancreatic trial of ZN-c3 plus gemcitabine ends early on toxicityOct 27Trial updategemcitabineZentalis Pharmaceuticals, Inc.
BMS: Reblozyl label supplement approved; GLORY CAR-T trial and BMS-986485 Phase 1 postedOct 22Weekly roundup, 4 itemsBristol Myers Squibbliso-celUpdated
Lilly posts two DC-806 Phase 1 DDI results; registers three new Phase 3 trialsOct 22Weekly roundup, 11 itemscetuximabdulaglutide
Imunon agrees to sell ThermoDox rights to VoxelDox TherapeuticsOct 21Clinical readoutEikon TherapeuticsGenmab A/S
Fred Hutchinson posts Phase II acalabrutinib results; AstraZeneca's AZD0780 LDL-C trial completesOct 16Weekly roundup, 11 itemsacalabrutinibAstraZenecaUpdated
Genentech lists Phase Ib KRAS G12D trial; Roche-sponsored DLBCL study shows updateOct 9Weekly roundup, 9 itemsalectinibcisplatinUpdated
Actuate Therapeutics files S-1 for 50 million share offering on NasdaqOct 6FinancingActuate Therapeutics Inc.
Revolution Medicines registers Phase 3 RASolute 309 in KRAS G12D pancreatic cancerSep 8Trial updatedaraxonrasibRevolution Medicines, Inc.
Incyte-backed trials: OSU tests pemigatinib cycling regimen; OHSU starts Opzelura pilot for PGAug 24Weekly roundup, 2 itemsIncyte Corporationpemigatinib
AbbVie posts results from terminated emraclidine trial, opens two studies to recruitmentAug 21Weekly roundup, 4 itemsAbbVieemraclidine
Can-Fite reports preclinical data on namodenoson-gemcitabine combination in pancreatic cancerAug 17Clinical readoutCan-Fite BioPharmagemcitabine
Incyte-linked filings this week: FIGHT-302 results posted, new academic pancreatic trial listedAug 14Weekly roundup, 2 itemsIncyte Corporationpemigatinib
RenovoRx completes Phase III enrollment, raises 2026 revenue guidanceAug 13Quarterly updateRenovoRx, Inc
Acrivon reports Q2 2026 results, flags ACR-368 interim data for second half of 2026Aug 12Quarterly updateACR-2316Acrivon Therapeutics
Theriva doses first patients in VIRAGE2 trial of VCN-01 in pancreatic cancerAug 11Quarterly updateTheriva Biologics, Inc.
Theriva doses first patient in VIRAGE2 trial testing repeat VCN-01 dosing in pancreatic cancerAug 6Trial updateTheriva Biologics, Inc.
Ocrevus higher-dose Phase 3 posts results, misses primary endpoint; two partner trials updateJul 24Weekly roundup, 4 itemsobinutuzumabocrelizumab
Molecular Partners reports progress in Phase 2 TACTIC trial of MP0317 for cholangiocarcinomaJul 20Clinical readoutMolecular Partners AG
BMS trials post results across lung cancer, sarcoma, myelofibrosis; new stroke study opensJul 17Weekly roundup, 5 itemsBristol Myers Squibblisocabtagene maraleucel
Theriva gets Spanish authorization for VIRAGE2 trial of VCN-01 in pancreatic cancerJul 7Clinical readoutTheriva Biologics, Inc.
Sanofi posts pediatric Hectorol results; USC germ cell trial data also reportedJul 2Weekly roundup, 4 itemsdoxercalciferolSanofi